Abstract
Background: Rufinamide (RUF) was granted orphan drug status in 2004 and it received approval for use in Europe in 2007 and by the US FDA in 2008 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children 4 years of age or older. RUF is generally well tolerated with common adverse effects (AE) such as somnolence, nausea, and vomiting being observed in up to 60% of treated children. AE are usually mild and self-limited; they are more frequently observed in titration phase than during maintenance. We report a patient with a newly diagnosed pancreatitis under RUF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
